A phase I/II trial of belinostat in combination with cisplatin, doxorubicin, and cyclophosphamide in thymic epithelial tumors: A clinical and translational study

Clinical Cancer Research

Volumn 20, Issue 21, 2014, Pages 5392-5402

  Thomas, Anish ^a   Rajan, Arun ^a   Szabo, Eva ^a   Tomita, Yusuke ^a   Carter, Corey A ^b   Scepura, Barbara ^a   Lopez Chavez, Ariel ^a   Lee, Min Jung ^a   Redon, Christophe E ^a   Frosch, Ari ^a   Peer, Cody J ^a   Chen, Yuanbin ^a   Piekarz, Richard ^a   Steinberg, Seth M ^a   Trepel, Jane B ^a   Figg, William D ^a   Schrump, David S ^a   Giaccone, Giuseppe ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

^b WALTER REED ARMY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BELINOSTAT; CISPLATIN; CYCLOPHOSPHAMIDE; DOXORUBICIN; HISTONE DEACETYLASE; ANTINEOPLASTIC AGENT; HYDROXAMIC ACID; SULFONAMIDE; TUMOR MARKER;

ADULT; AGED; ANEMIA; AREA UNDER THE CURVE; ARTICLE; BRADYCARDIA; CANCER COMBINATION CHEMOTHERAPY; CD8+ T LYMPHOCYTE; CLINICAL ARTICLE; CLINICAL STUDY; CONTINUOUS INFUSION; DIARRHEA; DRUG CLEARANCE; DRUG DOSE ESCALATION; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG ELIMINATION; DRUG HALF LIFE; DRUG SAFETY; DRUG WITHDRAWAL; ELECTROLYTE DISTURBANCE; ENTEROCOLITIS; ENZYME ACTIVITY; FAINTNESS; FATIGUE; FEBRILE NEUTROPENIA; FEMALE; HEARING IMPAIRMENT; HEART ATRIUM FIBRILLATION; HEART DISEASE; HISTONE ACETYLATION; HUMAN; HUMAN CELL; HYPERMAGNESEMIA; HYPERTRANSAMINASEMIA; HYPOALBUMINEMIA; HYPOCALCEMIA; HYPOKALEMIA; HYPOMAGNESEMIA; HYPONATREMIA; HYPOPHOSPHATEMIA; HYPOXIA; IMMUNOMODULATION; KIDNEY FAILURE; LEUKOPENIA; LUNG EMBOLISM; LUNG INFECTION; LYMPHOCYTOPENIA; MALE; MAXIMUM PLASMA CONCENTRATION; MAXIMUM TOLERATED DOSE; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUTROPENIA; NONCARDIAC CHEST PAIN; PAIN; PERIPHERAL EDEMA; PHARMACODYNAMICS; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PLASMA CONCENTRATION-TIME CURVE; PROGRESSION FREE SURVIVAL; QT PROLONGATION; REGULATORY T LYMPHOCYTE; THROMBOCYTOPENIA; THROMBOEMBOLISM; THYMOMA; THYMUS CANCER; THYMUS SURGERY; TRANSLATIONAL RESEARCH; TREATMENT OUTCOME; TUMOR LYSIS SYNDROME; URINARY TRACT INFECTION; VOMITING; CLINICAL TRIAL; DRUG EFFECTS; METABOLISM; MIDDLE AGED; NEOPLASMS, GLANDULAR AND EPITHELIAL; PROCEDURES; THYMUS NEOPLASMS; YOUNG ADULT;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BIOMARKERS, TUMOR; CD8-POSITIVE T-LYMPHOCYTES; CISPLATIN; CYCLOPHOSPHAMIDE; DOXORUBICIN; FEMALE; HUMANS; HYDROXAMIC ACIDS; MALE; MAXIMUM TOLERATED DOSE; MIDDLE AGED; NEOPLASMS, GLANDULAR AND EPITHELIAL; SULFONAMIDES; THYMUS NEOPLASMS; TRANSLATIONAL MEDICAL RESEARCH; YOUNG ADULT;

EID: 84908689205     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-14-0968     Document Type: Article

References (41)

1. Engels EA, Pfeiffer RM. Malignant thymoma in the United States: demographic patterns in incidence and associations with subsequent malignancies. Int J Cancer 2003;105:546-51.
2. Suster S, Moran CA. Histologic classification of thymoma: the World Health Organization and beyond. Hematol Oncol Clin North Am 2008;22:381-92.
3. Masaoka A, Monden Y, Nakahara K, Tanioka T. Follow-up-study of thymomas with special reference to their clinical stages. Cancer 1981;48:2485-92.
4. Chen G, Marx A, Chen WH, Yong J, Puppe B, Stroebel P, et al. New WHO histologic classification predicts prognosis of thymic epithelial tumors - A clinicopathologic study of 200 thymoma cases from China. Cancer 2002;95:420-9.
5. Kelly RJ, Petrini I, Rajan A, Wang Y, Giaccone G. Thymic malignancies: from clinical management to targeted therapies. J Clin Oncol 2011;29:4820-7.
6. The National Comprehensive Cancer Network Guidelines. Thymomas and thymic carcinomas. 2013 [cited 2013 Nov 24]; Available from: http://www.nccn.org/professionals/physician-gls/pdf/thymic.pdf.
7. Loehrer PJ Sr, Kim K, Aisner SC, Livingston R, Einhorn LH, Johnson D, et al. Cisplatin plus doxorubicin plus cyclophosphamide in metastatic or recurrent thymoma: final results of an intergroup trial. The Eastern Cooperative Oncology Group, Southwest Oncology Group, and Southeastern Cancer Study Group. J Clin Oncol 1994;12:1164-8.
8. Khan O, La Thangue NB. HDAC inhibitors in cancer biology: emerging mechanisms and clinical applications. Immunol Cell Biol 2012;90:85-94.
9. Marks PA, Rifkind RA, Richon VM, Breslow R. Inhibitors of histone deacetylase are potentially effective anticancer agents. Clin Cancer Res 2001;7:759-60.
10. Molife LR, de Bono JS. Belinostat: clinical applications in solid tumors and lymphoma. Expert Opin Investig Drugs 2011;20:1723-32.
11. Giaccone G, Rajan A, Berman A, Kelly RJ, Szabo E, Lopez-Chavez A, et al. Phase II study of belinostat in patients with recurrent or refractory advanced thymic epithelial tumors. J Clin Oncol 2011;29:2052-9.
12. Kim MS, Blake M, Baek JH, Kohlhagen G, Pommier Y, Carrier F. Inhibition of histone deacetylase increases cytotoxicity to anticancer drugs targeting DNA. Cancer Res 2003;63:7291-300.
13. Kurz EU, Wilson SE, Leader KB, Sampey BP, Allan WP, Yalowich JC, et al. The histone deacetylase inhibitor sodium butyrate induces DNA topoisomerase II alpha expression and confers hypersensitivity to etoposide in human leukemic cell lines. Mol Cancer Ther 2001;1:121-31.
14. Sharma SV, Lee DY, Li B, Quinlan MP, Takahashi F, Maheswaran S, et al. Ac hromatin-mediated reversible drug-tolerant state in cancer cell subpopulations. Cell 2010;141:69-80.
15. Redon CE, Nakamura AJ, Gouliaeva K, Rahman A, Blakely WF, Bonner WM. The use of gamma-H2AX as a biodosimeter for total-body radiation exposure in non-human primates. PLoS ONE 2010;5:e15544.
16. Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 2009;45:228-47.
17. Luchenko VL, Salcido CD, Zhang Y, Agama K, Komlodi-Pasztor E, Murphy RF, et al. Schedule-dependent synergy of histone deacetylase inhibitors with DNA damaging agents in small cell lung cancer. Cell Cycle 2011;10:3119-28.
18. Nakagawa T, Takeuchi S, Yamada T, Ebi H, Sano T, Nanjo S, et al. EGFR-TKI resistance due to BIM polymorphism can be circumvented in combination with HDAC inhibition. Cancer Res 2013;73:2428-34.
19. Zhang Y, Jung M, Dritschilo A. Enhancement of radiation sensitivity of human squamous carcinoma cells by histone deacetylase inhibitors. Radiat Res 2004;161:667-74.
20. Chai G, Li L, Zhou W, Wu L, Zhao Y, Wang D, et al. HDAC inhibitors act with 5-aza-2′-deoxycytidine to inhibit cell proliferation by suppressing removal of incorporated abases in lung cancer cells. PLoS ONE 2008;3:e2445.
21. Steele NL, Plumb JA, Vidal L, Tjørnelund J, Knoblauch P, Rasmussen A, et al. A phase 1 pharmacokinetic and pharmacodynamic study of the histone deacetylase inhibitor belinostat in patients with advanced solid tumors. Clin Cancer Res 2008;14:804-10.
22. Lassen U, Molife LR, Sorensen M, Engelholm SA, Vidal L, Sinha R, et al. A phase I study of the safety and pharmacokinetics of the histone deacetylase inhibitor belinostat administered in combination with carboplatin and/or paclitaxel in patients with solid tumours. Br J Cancer 2010;103:12-7.
23. Steele NL, Plumb JA, Vidal L, Tjørnelund J, Knoblauch P, Buhl-Jensen P, et al. Pharmacokinetic and pharmacodynamic properties of an oral formulation of the histone deacetylase inhibitor Belinostat (PXD101). Cancer Chemother Pharmacol 2011;67:1273-9.
24. Yeo W, Chung HC, Chan SL, Wang LZ, Lim R, Picus J, et al. Epigenetic therapy using belinostat for patients with unresectable hepatocellular carcinoma: a multicenter phase I/II study with biomarker and pharmacokinetic analysis of tumors from patients in the Mayo Phase II Consortium and the Cancer Therapeutics Research Group. J Clin Oncol 2012;30:3361-7.
25. Yokoi K, Matsuguma H, Nakahara R, Kondo T, Kamiyama Y, Mori K, et al. Multidisciplinary treatment for advanced invasive thymoma with cisplatin, doxorubicin, and methylprednisolone. J Thorac Oncol 2007;2:73-8.
26. Fornasiero A, Daniele O, Ghiotto C, Sartori F, Rea F, Piazza M, et al. Chemotherapy of invasive thymoma. J Clin Oncol 1990;8:1419-23.
27. Kawashima Y, Inoue A, Sugawara S, Harada M, Kobayashi K, Kozuki T, et al. Phase II study of amrubicin and carboplatin for invasive thymoma and thymic carcinoma: NJLCG0803. J Clin Oncol 2013;31 (suppl; abstr 7530).
28. Kim ES, Putnam JB, Komaki R, Walsh GL, Ro JY, Shin HJ, et al. Phase II study of a multidisciplinary approach with induction chemotherapy, followed by surgical resection, radiation therapy, and consolidation chemotherapy for unresectable malignant thymomas: final report. Lung Cancer 2004;44:369-79.
29. Kondo K, Monden Y. Lymphogenous and hematogenous metastasis of thymic epithelial tumors. Ann Thorac Surg 2003;76:1859-64.
30. Lin CS, Kuo KT, Hsu WH, Huang BS, Wu YC, Hsu HS, et al. Management of locally advanced unresectable thymic epithelial tumors. J Chin Med Assoc 2004;67:172-8
31. Cashen A, Juckett M, Jumonville A, Litzow M, Flynn PJ, Eckardt J, et al. Phase II study of the histone deacetylase inhibitor belinostat (PXD101) for the treatment of myelodysplastic syndrome (MDS). Ann Hematol 2012;91:33-8.
32. Thomas A, Shanbhag S, Haglund K, Berman A, Jakopovic M, Szabo E, et al. Characterization and management of cardiac involvement of thymic epithelial tumors. J Thorac Oncol 2013;8:246-9.
33. Brode S, Cooke A. Immune-potentiating effects of the chemotherapeutic drug cyclophosphamide. Crit Rev Immunol 2008;28:109-26.
34. Tao R, de Zoeten EF, Ozkaynak E, Chen C, Wang L, Porrett PM, et al. Deacetylase inhibition promotes the generation and function of regulatory T cells. Nat Med 2007;13:1299-307.
35. Shen L, Pili R. Class I histone deacetylase inhibition is a novel mechanism to target regulatory T cells in immunotherapy. Oncoimmunology 2012;1:948-50.
36. Strobel P, Rosenwald A, Beyersdorf N, Kerkau T, Elert O, Murumägi A, et al. Selective loss of regulatory T cells in thymomas. Ann Neurol 2004;56:901-904.38.
37. Fourcade J, Sun Z, Benallaoua M, Guillaume P, Luescher IF, Sander C, et al. Upregulation of Tim-3 and PD-1 expression is associated with tumor antigen-specific CD8+ T cell dysfunction in melanoma patients. J Exp Med 2010;207:2175-86.
38. Sakuishi K, Apetoh L, Sullivan JM, Blazar BR, Kuchroo VK, Anderson AC. Targeting Tim-3 and PD-1 pathways to reverse T cell exhaustion and restore anti-tumor immunity. J Exp Med 2010;207:2187-94.
39. Gartel AL. The conflicting roles of the cdk inhibitor p21(CIP1/WAF1) in apoptosis. Leuk Res 2005;29:1237-8.
40. Mineo TC, Ambrogi V, Mineo D, Baldi A. Long-term disease-free survival of patients with radically resected thymomas: relevance of cell-cycle protein expression. Cancer 2005;104:2063-71.
41. Kuo LJ, Yang LX. Gamma-H2AX - a novel biomarker for DNA doublestr- and breaks. In Vivo 2008;22:305-9.